Stem Holdings, Inc.

Stem Holdings, Inc. operates as a vertically-integrated cannabis products and technology company. It engages in the production, distribution, and sale of cannabis and cannabis-infused products. The company's brands include TJ's Gardens, TravisxJames, and Yerba Buena flower and extracts; Cannavore edible confections; Doseology, a CBD mass-market brand; and delivery-as-a-service brands of Budee and Ganjarunner e-commerce platforms. As of September 30, 2021, it had ownership interests in 29 state issued cannabis licenses, including 9 licenses for cannabis cultivation; 3 licenses for cannabis processing; 2 licenses for cannabis wholesale distribution; 3 licenses for hemp production; 7 cannabis dispensary licenses; and 5 licenses for adult-use medical retailers. The company was incorporated in 2016 and is headquartered in Boca Raton, Florida.

Stem Holdings, Inc. trades as STMH on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$19.02M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Stem Holdings, Inc. can be compared against peers such as Cannabis Suisse Corp., Indocan Resources Inc., MC Endeavors, Inc., Next Generation Management Corp., Nutra Pharma Corp., NeutriSci International Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $667, beta of 0.79, and return on equity of +1107.0%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

STMH currently shows total debt of $2.34M and beta of 0.79. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 15-12G/A (2024-09-16 00:00:00), 15-12G (2024-07-02 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://stemholdings.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.